These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31584195)

  • 21. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
    Grivas PD; Day KC; Karatsinides A; Paul A; Shakir N; Owainati I; Liebert M; Kunju LP; Thomas D; Hussain M; Day ML
    Mol Med; 2013 Nov; 19(1):367-76. PubMed ID: 24166682
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer.
    Fischer A; Wolf I; Fuchs H; Masilamani AP; Wolf P
    Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33260619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted delivery of an ADP-ribosylating bacterial toxin into cancer cells.
    Zahaf NI; Lang AE; Kaiser L; Fichter CD; Lassmann S; McCluskey A; Augspach A; Aktories K; Schmidt G
    Sci Rep; 2017 Jan; 7():41252. PubMed ID: 28128281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.
    Qi Z; Qiu Y; Wang Z; Zhang H; Lu L; Liu Y; Mathes D; Pomfret EA; Gao D; Lu SL; Wang Z
    Mol Oncol; 2021 Apr; 15(4):1054-1068. PubMed ID: 33540470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates.
    de Goeij BE; Satijn D; Freitag CM; Wubbolts R; Bleeker WK; Khasanov A; Zhu T; Chen G; Miao D; van Berkel PH; Parren PW
    Mol Cancer Ther; 2015 May; 14(5):1130-40. PubMed ID: 25724665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
    Mishra G; Panwar P; Mishra AK
    Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
    Liu S; Wang H; Currie BM; Molinolo A; Leung HJ; Moayeri M; Basile JR; Alfano RW; Gutkind JS; Frankel AE; Bugge TH; Leppla SH
    J Biol Chem; 2008 Jan; 283(1):529-540. PubMed ID: 17974567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal Growth Factor Receptor and Ki-67 as Predictive Biomarkers Identify Patients Who Will Be More Sensitive to Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Radical Nephroureterectomy.
    Long X; Zu X; Li Y; He W; Hu X; Tong S; Wang Z; Chen M; Qi L
    PLoS One; 2016; 11(11):e0166884. PubMed ID: 27870887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthrax fusion protein therapy of cancer.
    Frankel AE; Powell BL; Duesbery NS; Vande Woude GF; Leppla SH
    Curr Protein Pept Sci; 2002 Aug; 3(4):399-407. PubMed ID: 12370003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
    Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
    Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal Growth Factor Receptor-Targeted Multifunctional Photosensitizers for Bladder Cancer Imaging and Photodynamic Therapy.
    Cheruku RR; Cacaccio J; Durrani FA; Tabaczynski WA; Watson R; Marko A; Kumar R; El-Khouly ME; Fukuzumi S; Missert JR; Yao R; Sajjad M; Chandra D; Guru K; Pandey RK
    J Med Chem; 2019 Mar; 62(5):2598-2617. PubMed ID: 30776232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation.
    Ren L; Yang X; Zhao L; Zhang H; Wang J
    Integr Cancer Ther; 2016 Mar; 15(1):80-6. PubMed ID: 26315609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the actions and interactions of retinoic acid and epidermal growth factor on transformed urothelial cells in culture: implications for the use of retinoid therapy in the treatment of bladder cancer patients.
    Nutting C; Chowaniec J
    Clin Oncol (R Coll Radiol); 1992 Jan; 4(1):51-5. PubMed ID: 1310606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
    Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
    Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria.
    Zeng J; Sun Y; Wu K; Li L; Zhang G; Yang Z; Wang Z; Zhang D; Xue Y; Chen Y; Zhu G; Wang X; He D
    Mol Cancer Ther; 2011 Jan; 10(1):104-16. PubMed ID: 21220495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.
    Mugabe C; Matsui Y; So AI; Gleave ME; Baker JH; Minchinton AI; Manisali I; Liggins R; Brooks DE; Burt HM
    Clin Cancer Res; 2011 May; 17(9):2788-98. PubMed ID: 21357680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.
    Hayashi T; Seiler R; Oo HZ; Jäger W; Moskalev I; Awrey S; Dejima T; Todenhöfer T; Li N; Fazli L; Matsubara A; Black PC
    J Urol; 2015 Oct; 194(4):1120-31. PubMed ID: 26047983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
    Uckun FM; Narla RK; Zeren T; Yanishevski Y; Myers DE; Waurzyniak B; Ek O; Schneider E; Messinger Y; Chelstrom LM; Gunther R; Evans W
    Clin Cancer Res; 1998 May; 4(5):1125-34. PubMed ID: 9607569
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.